| Diagnosis and management of varicose veins in the legs: summary of NICE guidance G Marsden, M Perry, K Kelley, AH Davies Bmj 347, 2013 | 220 | 2013 |
| Gene therapy: evidence, value and affordability in the US health care system G Hampson, A Towse, SD Pearson, WB Dreitlein, C Henshall Journal of comparative effectiveness research 7 (1), 15-28, 2018 | 133 | 2018 |
| Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare B Jönsson, G Hampson, J Michaels, A Towse, JMG von der Schulenburg, ... The European journal of health economics 20, 427-438, 2019 | 127 | 2019 |
| Real-world evidence for coverage decisions: opportunities and challenges G Hampson, A Towse, WB Dreitlein, C Henshall, SD Pearson Journal of comparative effectiveness research 7 (12), 1133-1143, 2018 | 101 | 2018 |
| Prevention and management of pressure ulcers in primary and secondary care: summary of NICE guidance G Stansby, L Avital, K Jones, G Marsden Bmj 348, 2014 | 97 | 2014 |
| A cost-effectiveness analysis of surgery, endothermal ablation, ultrasound-guided foam sclerotherapy and compression stockings for symptomatic varicose veins G Marsden, M Perry, A Bradbury, N Hickey, K Kelley, H Trender, ... European Journal of Vascular and Endovascular Surgery 50 (6), 794-801, 2015 | 62 | 2015 |
| Applying a multicriteria decision analysis (MCDA) approach to elicit Stakeholders’ preferences in Italy: the case of Obinutuzumab for rituximab-refractory indolent non-Hodgkin … M Garau, G Hampson, N Devlin, NA Mazzanti, A Profico PharmacoEconomics-Open 2, 153-163, 2018 | 41 | 2018 |
| Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects G Hampson, TH Ward, J Cummings, M Bayne, AL Tutt, MS Cragg, C Dive, ... Journal of immunological methods 360 (1-2), 30-38, 2010 | 36 | 2010 |
| A cost‐effectiveness analysis of two different repositioning strategies for the prevention of pressure ulcers G Marsden, K Jones, J Neilson, L Avital, M Collier, G Stansby Journal of advanced nursing 71 (12), 2879-2885, 2015 | 31 | 2015 |
| The cost-effectiveness of shopping to a predetermined grocery list to reduce overweight and obesity N Au, G Marsden, D Mortimer, PK Lorgelly Nutrition & diabetes 3 (6), e77-e77, 2013 | 31 | 2013 |
| An economic analysis of human milk supplementation for very low birth weight babies in the USA G Hampson, SLE Roberts, A Lucas, D Parkin BMC pediatrics 19, 1-9, 2019 | 30 | 2019 |
| A review of NICE methods and processes across health technology assessment programmes: why the differences and what is the impact? E Cowles, G Marsden, A Cole, N Devlin Applied health economics and health policy 15, 469-477, 2017 | 24 | 2017 |
| Does a biomedical research centre affect patient care in local hospitals? CA Lichten, G Marsden, A Pollitt, V Kiparoglou, KM Channon, J Sussex Health research policy and systems 15, 1-25, 2017 | 20 | 2017 |
| A review of NICE Methods across health technology assessment programmes: differences, justifications and implications E Brockis, G Marsden, A Cole, N Devlin London, The Office of Health Economics (OHE), 2016 | 19 | 2016 |
| A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions SD Pearson, WB Dreitlein, A Towse, G Hampson, C Henshall Journal of comparative effectiveness research 7 (12), 1145-1152, 2018 | 18 | 2018 |
| A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity A Gibb, A Greystoke, M Ranson, K Linton, S Neeson, G Hampson, ... British journal of cancer 109 (10), 2560-2565, 2013 | 16 | 2013 |
| Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5‐year results from a UK … TM Illidge, HS McKenzie, S Mayes, A Bates, AJ Davies, R Pettengell, ... British journal of haematology 173 (2), 274-282, 2016 | 15 | 2016 |
| Exploring the assessment and appraisal of regenerative medicines and cell therapy products: is the NICE approach fit for purpose? G Hampson, A Towse Contract Research, 2017 | 14 | 2017 |
| Cost-effectiveness analysis: role and implications G Marsden, D Wonderling Phlebology 28 (1_suppl), 135-140, 2013 | 11 | 2013 |
| Rituximab cerebrospinal fluid levels in patients with primary central nervous system lymphoma treated with intravenous high dose rituximab JF Larouche, M Bergeron, G Hampson, T Illidge, R Delage Blood, The Journal of the American Society of Hematology 118 (21), 1644-1644, 2011 | 10 | 2011 |
